KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, et al. Cancer Cell 2025 Jul 5:S1535-6108(25)00261-2. doi: 10.1016/j.ccell.2025.

Read + Share

Amedeo Smart

Independent Medical Education

Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, et al. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell 2025 Jul 5:S1535-6108(25)00261-2. doi: 10.1016/j.ccell.2025.
PMID: 40645185